|
|
|
|
Schering-Plough reports positive interim results from Phase II hepatitis study
In a 48-week boceprevir regimen, the sustained virologic response (SVR) rate was 74% at 12 weeks after the end of treatment (SVR 12) in patients who received four weeks of Pegintron and Rebetol prior to the addition of boceprevir ...
|
|
|
Schering-Plough reports positive interim results from Phase II hepatitis study
(Datamonitor via COMTEX) -- SGP | Quote | Chart | News | PowerRating -- Schering-Plough has reported that a planned interim analysis of a Phase II study showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Oct 31-Nov 1 2008 San Francisco, CA Sat, 01 Nov 2008 15:01:00 GMT Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1, 2008 /PRNewswire-FirstCall/ -- Schering...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Schering-Plough says Boceprevir Phase II Study Showed Rate of Sustained Response With 28- and 48-Week Regimens
(RTTNews) - Schering-Plough Corp.(SGP: News ) said on Saturday that a planned interim analysis of a Phase II study showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon and...
|
|
|
Schering-Plough says Boceprevir Phase II Study Showed Rate of Sustained Response With 28- and 48-Week Regimens
(RTTNews) - Schering-Plough Corp.(SGP) said on Saturday that a planned interim analysis of a Phase II study showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon and ribavirin...
|
|
|
Schering-Plough Reports Financial Results for Third Quarter of 2008
KENILWORTH, N.J., Oct.21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported financial results for the third quarter of 2008. 'Our performance this quarter again demonstrates the strength of our long-term strategies and...
|
|
|
Schering-Plough Reports Financial Results for Third Quarter of 2008
/PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported financial results for the third quarter of 2008.'Our performance this quarter again demonstrates the strength of our long-term strategies and our ability to execute on...
|
|
|
Schering Plough Corp Says Q3 Gaap Net Sales Of Rebetol $63 Mln
ews NEW YORK (Thomson Financial) - Chuck Mikolajczak cm COPYRIGHT Copyright Thomson Financial News Limited 2007.All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or...
|
|
|
3rd Quarter Results
Schering-Plough Reports Financial Results for Third Quarter of 2008 Strong Financial Performance Driven By Strength and Diversity on Many Fronts; Productivity Transformation Taking Hold KENILWORTH, N.J., Oct.21 -- Schering-Plough...
|
|
|
Schering-Plough Reports Financial Results for Third Quarter of 2008
KENILWORTH, N.J., Oct.21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial results for the third quarter of 2008. 'Our performance this quarter again demonstrates the strength of our long-term...
|
|
|
BRIEF-Schering-Plough Q3 results
Q3 GAAP EARNINGS PER SHARE $0.34 Q3 SALES $5.1 BILLION SAYS GAAP NET SALES FOR THE 2008 THIRD QUARTER TOTALED $4.6 BILLION Q3 EARNINGS PER SHARE $0.39, EX ITEMS QTRLY SALES OF REMICADE INCREASED 32 PERCENT TO $564 MILLION SAYS SALES OF...
|
|
|
Schering Plough Corp Says Q3 Gaap Net Sales Of Rebetol $63 Mln
The pricing, performance and/or news information provided above is only for your personal information and use and is not intended to address your particular requirements or to be relied upon in making (or refraining from making) any specific...
|
|
|
Schering-Plough Reports Financial Results for Third Quarter of 2008
Strong Financial Performance Driven By Strength and Diversity on Many Fronts; Productivity Transformation Taking Hold KENILWORTH, N.J., Oct.21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial...
|
|
|
Schering Plough Corp Says Q3 Gaap Net Sales Of Rebetol $63 Mln
NEW YORK (Thomson Financial) - Chuck Mikolajczak cm COPYRIGHT Copyright Thomson Financial News Limited 2007.All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or...
|
|
|
BRIEF-Schering-Plough Q3 results
- Oct 21 (Reuters) - Schering-Plough Corp: * Q3 GAAP earnings per share $0.34 * Q3 sales $5.1 billion * Says GAAP net sales for the 2008 third quarter totaled $4.6 billion * Q3 earnings per share $0.39, ex items * Qtrly sales of remicade...
|
|
|
Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy
Jnl of Viral Hepatitis Sept 2008 T.-M.Scherzer 1 , K. Reddy 2 , F. Wrba 3 , H. Hofer 1 , K. Staufer 1 , P. Steindl-Munda 1 , A. Gangl 1 and P. Ferenci 1 1 Department of Internal Medicine III, Division of Gastroenterology and...
|
